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Egypt, the single country with highest incidence of HCV infection in the world, has embarked
on a government-sponsored mass treatment program using several combinations of DAAs.
Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a sub-
committee was assigned to develop national guidelines for respective prioritizing indications and
protocols. It evaluated the beneﬁt of treating patients with different extrahepatic manifestations,
and reviewed relevant clinical trials and guidelines concerning DAA combinations available in
Egypt. The latter included Sofosbuvir plus either peg-interferon, Simeprevir, Ledipasvir or
daclatasvir, and the Viekera family comprising paritaprevir/ritonavir + ombitasvir with (GT-
1) or without (GT-4) Dasabuvir. Any of these protocols may be used with or without Ribavirin
according to indication. A blueprint was subjected to peer debate in dedicated workshops in two
national meetings and subsequently to an online professional review, eventually leading to a
ﬁnal report that was adopted by the health authorities. Seven compelling and 10 optional indi-
cations were identiﬁed for treating patients with predominantly extrahepatic manifestations.
The former include kidney disease at different stages, cryoglobulinemic vasculitis and non-
Hodgkin lymphoma. Selected treatment protocols, were encoded and their use was prioritized
on the basis of evidence of efﬁcacy and safety. We concluded that any of the studied protocols
may be used, preferably with ribavirin, for 12-week treatment in all patients with extrahepatic
manifestations without cirrhosis and with eGFR above 30 ml/min/1.73 sqm. Ribavirin should
be included in protocols for treating patients with compensated cirrhosis. Daclatasvir-based
protocols are recommended for decompensated cirrhosis, while the Viekera family is recom-
mended in patients with eGFR< 30 ml/min/1.73 sqm, including those on dialysis. In kidney-
transplanted patents, caution is due to avoidance of the pharmacokinetic interaction with the
Cytochrome-P450 enzyme system, in-between immunosuppressive agents and most DAAs, par-
ticularly the Viekera family.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
The remarkable success of the current wave of Direct Antiviral
Agents (DAAs) against Hepatitis C virus (HCV) offers an
unprecedented cure opportunity for millions of patients world-
wide. Sustained viral response 12 weeks after completion of
treatment (SVR12) is currently achievable in the vast majority,
which predicts viral eradication in 98% of patients. This is
associated with recovery from most clinical sequelae of HCV
infection [1], and provides a survival advantage to many sub-
sets of patients, including reduction of cardiovascular mortal-
ity. This imposes a moral responsibility on the health
authorities to offer treatment to all infected patients, regardless
of the extent of clinical disease.
Meeting this goal in Egypt is a hard challenge, because; (a)
it is a unique country where the virus has its highest impact in
the world (serological prevalence of 13.9–15.5% (14.7%) [2];
positive nucleic acid test in 7.0–12.2% (9.8%) [3]); (b) the
prevalent viral strain in 90% of patients is Genotype-4 (GT-
4) [4], which is typically difﬁcult to treat, and on which only
a few therapeutic trials have been published; and (c) the avail-
able health budget cannot accommodate the high demand for
mass treatment.
Nevertheless, the ambitious strategic decision in Egypt is to
treat millions of infected patients in successive stages, which
requires a comprehensive prioritization system. This was devel-
oped according to the extent of liver damage and according to
Child-Pugh criteria and MELD score, and implemented for the
treatment of the ﬁrst 60,000 patients. But it was soon realized
that prioritization according to hepatic criteria refutes many
patients with predominantly extrahepatic manifestations,which may be even more life threatening despite relatively
low liver scores. Accordingly, a subcommittee of the Egyptian
National Commission for Viral Hepatitis was assigned the task
of developing a prioritization system for patients with extra-
hepatic manifestations regardless of the extent of liver affec-
tion. The subcommittee was also required to prioritize the
treatment protocols for those patients, limiting the choices to
those available in the country.Process
The subcommittee was composed of 7 members: 4 nephrolo-
gists, 2 rheumatologists and a hepatologist. They were pro-
vided with a list of approved DAAs, as well as those under
local clinical trial, pending registration in Egypt.
A ﬁve-step action plan was developed and completed in
9 months.
1. Literature survey for evidence of:
a. Beneﬁt from treatment of different extrahepatic
manifestations
b. Preferred treatment protocols for extrahepatic
manifestations
2. Selecting evidence-based protocols that meet the local
needs
3. Peer debate
4. Online professional survey
5. Preparation of the ﬁnal documents for publishing and
governmental implementation.
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 The basic pharmacokinetics of each drug on the avail-
ability list provided by the Egyptian National Commis-
sion for Viral Hepatitis (ENCVH) were reviewed, with
emphasis on its protein binding, metabolism, excretion,
half-life with normal or impaired glomerular ﬁltration
rate, dialyzability, major drug–drug interactions and tar-
get viral proteins.
 Randomized Clinical Trials (RCTs) on each DAA were
screened by Medline search and manufacturers’ websites.
These were tabulated and shortlisted according to their
relevance.
 Approval status of individual drugs as well as combination
protocols by regulatory authorities in the USA (FDA)
and Europe (EMA) was obtained from their respective
websites.
 Recommendations made by the following guideline initia-
tives were reviewed and integrated. The respective terms
for the strength of evidence and recommendations were
used where applicable.Table 1 Rating by AASLD-IDSA classiﬁcation and level of eviden
Description
AASLD classification
AASLD Class I Conditions for wh
evaluation, proced
AASLD Class II Conditions for wh
the usefulness and
AASLD Class IIa Weight of evidenc
AASLD Class IIb Usefulness and eﬃ
AASLD Class III Conditions for wh
evaluation, proced
be harmful
Level of Evidence
Level A Data derived from
Level B Data derived from
Level C Consensus opinion
Table 2 Evidence grading used by the European Society of Liver D
Notes
Evidence quality
High Further research is very unli
conﬁdence in the estimate of
Moderate Further research is likely to h
on our conﬁdence in the esti
change the estimate
Low Further research is very like
impact on our conﬁdence in
is likely to change the estima
estimate is uncertain
Recommendation
Strong Factors inﬂuencing the stren
recommendation included th
presumed patient-important
Weak Variability in preferences an
uncertainty. Recommendatio
certainty, higher cost or reso American Association for the Study of Liver Disease
(AASLD) and Infectious Diseases Society of America
(IDSA) issued in August 2015 [5] (Table 1).
 European Association for the Study of the Liver (EASL),
June 2015 [6] (Table 2).
 Kidney Disease: Improvement of Global Outcomes
(KDIGO), April 2008 [7] (Table 3).
 ‘‘Real Life” observational data of the Hepatitis C Therapeu-
tic Registry and Research Network (HCV-TARGET) [8].Protocol prioritization
Four factors were taken into consideration while prioritizing
DAA combinations in different clinical settings.
Genotype
1. Higher priority to documented efﬁcacy against GT-4.
2. Approved anti-GT-1 combinations including pangenotypic
agents, usually targeting NS5B nucleoside inhibitors.ce [AASLD-IDSA 2015] [15].
ich there is evidence and/or general agreement that a given diagnostic
ure, or treatment is beneﬁcial, useful, and eﬀective
ich there is conﬂicting evidence and/or a divergence of opinion about
eﬃcacy of a diagnostic evaluation, procedure, or treatment
e and/or opinion is in favor of usefulness and eﬃcacy
cacy are less well established by evidence and/or opinion
ich there is evidence and/or general agreement that a diagnostic
ure, or treatment is not useful and eﬀective or if it in some cases may
multiple randomized clinical trials, meta-analyses, or equivalent
a single randomized trial, nonrandomized studies, or equivalent
of experts, case studies, or standard of care
isease [EASL 2015] [16].
Grading
kely to change our
eﬀect
A
ave an important impact
mate of eﬀect and may
B
ly to have an important
the estimate of eﬀect and
te. Any change of
C
gth of the
e quality of the evidence,
outcomes, and cost
1
d values, or more
n is made with less
urce consumption
2
Table 3 Levels of strength of recommendations used by the Kidney Disease: Improvement of Global Outcomes [KDIGO 2008] [17].
Strength of recommendation Wording of recommendation Basis for strength of recommendation
Strong An intervention ‘should’ be done High’ quality evidence and/or other considerations support a
strong guideline
Moderate An intervention ‘should be considered’ ‘Moderate’ quality evidence and/or other considerations support a
moderate guideline
Weak An intervention ‘is suggested’ ‘Low’ or ‘Very Low’ quality evidence; predominantly based on
expert judgment for good clinical practice
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1. Proven efﬁcacy in RCTs.
2. Approved combinations by credible regulatory authorities
for speciﬁc clinical settings.
3. Higher grading in recognized guideline recommendations.Efficacy, toxicity and duration of therapy
1. Higher SVR 12 in respective clinical settings.
2. Lower incidence and signiﬁcance of reported adverse drug
reactions.
3. Preference of Interferon-free regimens.
4. Preference of Ribavirin-free regimens in the absence of cir-
rhosis and in patients with Stages IV–V CKD
(eGFR< 30 ml/min/1.73 sqm).
5. Shorter duration of treatmentTable 4 Scoring of patients with CKD for DAA treatment
priority.
Positive points
Post-renal transplant 5 points
Regular Dialysis 5 points
Cryoglobulinemic vasculitis 5 points
Non-Hodgkin B-cell lymphoma 5 points
Biopsy conﬁrmed MCGN
with hypocomplementemia
4 points
Biopsy-conﬁrmed MCGN without
hypocomplementemia
3 points
Nephrotic syndrome regardless
of histological type
2 points
Previous treatment failure 2 points
HBV/HIV/CMV co-infection 2 points
Stage of kidney disease (MDRD-4) 1 point/stage
Stage of liver disease (Fibroscan) 1 point/stage
Negative points
Age >70 1 point/5 years
Decompensated cirrhosis 3 points
Concurrent drug–drug interaction
with selected Protocol
3 points
Concomitant heart disease 1 point/NYHA score
Concomitant pulmonary disease 1 point/10% FVC1
Concomitant CNS disease 1 point/10% disabilityPharmacokinetics
In the absence of credible evidence in certain clinical settings,
the pharmacokinetic and pharmacodynamic features of indi-
vidual drugs were the basis of suggestion for clinical use, par-
ticularly with regard to the following:
1. Pharmacokinetics in impaired kidney function.
2. Dialyzability and/or extent of protein-binding (when used
in dialysis patients).
3. Drug–drug interaction with immunosuppressive agents
(when used post-transplantation).
4. Drug–drug interaction with common medications for co-
morbid conditions.
5. Spectrum of antiviral action in multiple viral co-infection.
Peer debate
The ﬁrst blueprint was distributed, presented and discussed in
2 dedicated workshops at the 34th national congress of the
Egyptian Society of Nephrology and Renal Transplantation,
and the 7th Annual Congress of The National Hepatology
and Tropical Medicine Research Institute, both in Cairo
(2015), leading to an amended version, approved by respective
national societies.
Online professional review
The amended version was subject to public review using the free
‘‘SurveyMonkey” online tool for one month starting 1stMarch2015. Participants included a selected cohort of experts,
as well as those who requested participation following
the congress discussions. Comments were reviewed by the
subcommittee and incorporated, where applicable, into the
ﬁnal document.
Final documents
1. An ofﬁcial report was submitted to the National Commis-
sion for Viral Hepatitis, along with a scoring list (Table 4),
for prioritizing patients according to relative urgency and
expected beneﬁt of treatment in different clinical settings,
score 5 being the highest. Relative limitations were
expressed as ‘‘negative points” in order to boot the priority
of those who are more likely to beneﬁt from treatment. An
arbitrary acceptance threshold of 10 points was set as a
beginning, based on the estimated numbers of patients in
relation to the immediately available budget. This threshold
would be lowered as funds become available for treating
more patients.
2. The report was reformatted into this article for formal sci-
entiﬁc publication.
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with the use of DAAs in HCV, and the long list of newer
agents in the pipeline, the committee is aware of the need
for frequent updating of its recommendations, which shall
be available through a website designed for easy reference
(under construction).
Guidelines
Based on the mentioned criteria, the subcommittee developed
the following clinical guidelines for Egyptian patients,
expressed as either ‘‘recommendations” or ‘‘suggestions”
according to the strength of evidence and level in reference
guidelines. For suggested items, treatment decision should be
made on individual case to case basis, granting priority to
higher severity scores and life threatening co-morbid condi-
tions that are likely to tolerate and beneﬁt from eradication
of HCV infection.
Section I. Indications for treatment
I. We suggest evaluating HCV-infected patients according to six
factors, namely:
1. The stage of liver disease.
2. Estimated glomerular ﬁltration rate, and nature of chronic
kidney disease (CKD) if present.
3. Nature and severity of extrahepatic manifestations.
4. Presence of co-morbid conditions and related chronic drug
administration.
5. Previous antiviral treatment with interferon or direct anti-
viral agents.
6. HCV genotyping only prior to prescribing the Viekera
family.
Stage of liver disease
II. We recommend that patients indicated for the treatment
due to their liver condition be treated according to standard
indications [9], implemented by the Egyptian National
HCV Control Program, based on ﬁbrosis stage (determined
by Fib4 calculation and ﬁbroscans when available) and
compensation of hepatocellular function (according to
Child-Pugh criteria and the Model for End-stage Liver
Disease (MELD)) scores.
Glomerular filtration rate
III. We recommend estimating the glomerular filtration rate
(eGFR) by the Modiﬁed Diet in Renal Disease (MDRD)
formula-4 [10] or Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) [11] for appropriate choice and dosing
of DAA combinations.
Nature of chronic kidney disease
IV. We recommend treatment of all HCV-infected patients with
any of the following conditions even in the absence of a com-
pelling liver indication or cryoglobulinemia:(a) Kidney transplant recipients [AASLD-IDSA-I, LB].
(b) Patients on the waiting list for kidney transplantation
[AASLD-IDSA-I, LB]; EASL-A1.
(c) Patients on regular dialysis [AASLD-IDSA-IIa, LC].
(d) Patents with mesangiocapillary (Membranoprolifera-
tive) glomerulonephritis [AASLD-IDSA-IIa, LB].
(e) Patients with the nephrotic syndrome due to any
histopathological type of glomerulonephritis [AASLD-
IDSA-IIa, LB].
V. We suggest treatment of patients with the following HCV-
related kidney disorders:
(a) Patients in CKD stages 3–5 (eGFR< 60 ml/
min/1.73 sqm), regardless of etiology [not graded)].
(b) De-novo HCV infection persisting for over 12 weeks
in patients with any grade CKD. (KDIGO 2008
[Weak]).
Extrahepatic manifestations
VI. We recommend DAA treatment for cryoglobulinemic
vasculitis with end-organ manifestations (joints, peripheral
nerves, skin, kidneys, lungs, eyes, gut, brain, etc.)
[AASLD-IDSA-I, LB], graded according to severity
[opinion].
VII. We recommend DAA treatment for HCV-associated
Non-Hodgkin B-cell lymphoma [12] [opinion].
VIII. We suggest DAA treatment for the following conditions
in the context of HCV infection, even in the absence of
cryoglobulinemia.
 Type 2 Diabetes mellitus (insulin resistant) [AASLD-IDSA-
IIa, LB].
 Debilitating fatigue [AASLD-IDSA-IIa, LB].
 Porphyria cutanea tarda. [13] [AASLD-IDSA-IIb, LC].
 Hodgkin’s lymphoma [14] and other lymphoproliferative
disorders [15] [not graded].
 Chronic arthritis of undetermined etiology [16] [not
graded].
 Autoimmune thrombocytopenia [not graded] [17].
 Oral [18] and cutaneous [19] Lichen planus [not graded].
 Low C4, positive rheumatoid factor, negative Anti-CCP,
yet with negative cryoglobulins [20] [opinion].
Co-morbid conditions
IX. We suggest investigating all patients before prescribing
DAAs for the presence of co-infection with HBV, HIV, or other
co-morbid conditions that may require modiﬁcations in
recommended treatment protocols [Opinion] (see guideline
XIV).Previous antiviral treatment
X. We recommend reviewing each patient’s history for previous
anti-HCV therapy with interferon, ribavirin or other DAAs
[EASL-A1], since this predicts viral non-structural protein
mutations and guides the selection of re-treatment protocols
(see guideline XIII).
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XI. We recommend genotyping only prior to treatment with the
Viekera family owing to the protocol variance in the treatment
of either GT-4 or GT-1 infection (see later). These constitute
the only genotypes reported in Egypt in a proportion of 9:1
respectively [4]. Genotyping is not recommended in candidates
for other protocols, which are equally effective in both
genotypes.
Section II. Treatment protocols
XII. We recommend individualization of the use of DAA proto-
cols for treatment-naive patients guided by the priorities shown
in Table 5
Selected protocols
Selected DAA combinations in this section are chronologically
ordered according to their availability in Egypt. Other DAAs,
even with better pharmacokinetics, FDA approval and inclu-
sion in international guidelines, are omitted. Selected protocols
are identiﬁed by letters A–E. Numbers following the letters dif-
ferentiate additional antiviral agents as follows: (1) no addi-
tions; (2) ribavirin in a weight-based ﬁxed dose; (3) ribavirin
in a reduced dose; and (4) interferon. The target non-
structural viral protein, the market name and manufacturer
are provided following each drug. A sufﬁxed asterisk indicates
modiﬁcation of a standard protocol. The common side effects
associated with their use are appended to each protocol. Rec-
ommendations for their use in different clinical conditions are
provided in Table 5.
Protocol A: Sofosbuvir (NS5B-Sovaldi)-based protocols
A2: Sofosbuvir (400 mg) and weight-based RBV (1000 mg
[<75 kg] to 1200 mg [>75 kg]) for 12 weeks [FDA
approved for GT-1] or 24 weeks [FDA approved for
GT-1 & GT-3], [Egyptian Ancestry Study in GT-4] [21].
A4: Sofosbuvir (400 mg) and weight-based RBV (1000 mg
[<75 kg] to 1200 mg [>75 kg]) plus weekly PEG-IFN
Alpha 2A (180 mcg subcutaneously) or PEG-IFN Alpha
2B (1.5 mcg/kg subcutaneously) for 12 weeks (Neutrino
Study [22], FDA approved for GT-1 & GT-4].
Adverse reactions. Over one-third of patients using Sofosbuvir
will complain of headache, fatigue and nausea; and 10–20%
will have insomnia, irritability, anemia, shortness of breath,
diarrhea, dermatitis and muscle aches. Some patients may
develop transient increase in serum bilirubin and lipase, which
resolve spontaneously.
Protocol B: Ledipasvir (NS5A)/sofosbuvir (NS5B) [Harvoni]-
based protocols
B1: Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir
(400 mg) for 12 weeks in GT-1 (ION studies [23–25]), or
GT-4 or GT-5 (GS-US-337-1119, O056 trial [26]); FDA
approved for 12-week treatment in GT-1 without cirrhosis,
or treatment-naı¨ve patients with cirrhosis; or for 24 weeks
GT-1 in treatment-experienced patients with cirrhosis];
NAID SYNERGY study for 12 weeks in GT-4 [27].
B2: Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir
(400 mg) plus weight-based Ribavirin (1000 mg [<75 kg]to 1200 mg [>75 kg]) for 12 weeks in GT-1 (ION studies
[23–25]), and GT-4 (SOLAR studies [28,29]).
Adverse reactions. Since Ledipasvir is invariably used with
Sofosbuvir, it is not possible to ﬁgure out the former’s inde-
pendent side effects. However, the reported frequency and
severity of adverse reactions with this protocol are much less
than with Protocol A combinations. They include headache
and fatigue in 15%, nausea in 8% and diarrhea in 5% of
patients. Transient elevation of serum lipase and bilirubin
has also been reported.
Protocol C: Simeprevir (NS3-Olysio) + sofosbuvir (NS5B)-
based protocols
C1: Simeprevir (150 mg) plus sofosbuvir (400 mg) for
12 weeks. (FDA approved for GT-1 without
(OPTIMIST-1) [30] or with (OPTIMIST-2) [31]
cirrhosis].
C1*: Simeprevir (150 mg) plus half-dose sofosbuvir (200 mg)
for 12 weeks (in GT-1 infection with renal insufﬁciency
[32]).
C2: Simeprevir (150 mg) plus sofosbuvir (400 mg) plus
weight-based RBV (1000 mg [<75 kg] to 1200 mg
[>75 kg]) for 12 weeks in GT-1 (COSMOS Study [33]).
C4: Simeprevir (150 mg) plus weight-based RBV (1000 mg
[<75 kg] to 1200 mg [>75 kg]) plus peg-interferon for
12 weeks (FDA approved for GT-1).
Adverse reactions. Much of the side effects of this protocol are
attributed to Sofosbuvir rather than Simeprevir. Fatigue,
headache and nausea occur in 20–25% of patients, insomnia,
diarrhea and muscle pains in about 15%, and dyspnea and
pruritus in 10%. Transient hyperbilirubinemia has been
reported in a minority.
Protocol D: Daclatasvir (NS5A-Daklinza, Clatazev)-based
protocols
D1: Daclatasvir (60 mg) plus sofosbuvir (400 mg) for 12 weeks
[Study AI444040 for GT-1,2,3; FDA-approved for GT-3]
[34].
D2: Daclatasvir (60 mg) plus sofosbuvir (400 mg) plus weight-
based RBV for 12 weeks [European Multicenter Compas-
sionate Use Program [35] for Genotypes 1,2,3,4].
D3: Daclatasvir (60 mg) plus sofosbuvir (400 mg) plus ﬁxed
dose RBV (600 mg) for 12 weeks (ALLY-I trial [36]).
D4: Daclatasvir (60 mg) plus weight-based RBV plus Inter-
feron for 24 weeks [COMMAND-4 Study in GT-4 [37]).
Adverse reactions. Daclatasvir is well tolerated, even in combi-
nation with Sofosbuvir. Fatigue and headache occur in less
than 15%, and nausea and diarrhea in less than 10% of cases.
Transient increase in serum lipase has been reported.
Protocol E: Paritaprevir (NS3)/ritonavir (CYP450 inhibitor)
+ ombitasvir (NS5A)-based protocols
E1: Paritaprevir (NS3)/ritonavir (CY450), ombitasvir (NS5A)
(AbbVie 2D, Viekerax, Technivie, Qurevo)] (PEARL-1
study [38], FDA approved for GT-4 with cirrhosis).
E1*: Paritaprevir (NS3)/ritonavir (CY450), ombitasvir
(NS5A) and dasabuvir (NS5B-Exviera) (AbbVie 3D,
Viekera Pack) (FDA approved for GT-1).
Table 5 Selected DAA treatment protocols for HCV-extrahepatic manifestations. Refer to text for protocol codes and citations of
RCTs and guideline recommendations. eGFR= estimated glomerular ﬁltration rate; RBV = Ribavirin; CyA = Cyclosporin-A;
TAC= Tacrolimus; SIR = Sirolimus; EVE = Everolimus.
eGFR [1]
>30ml/min/1.73sqm <30ml/min/1.73sqm
Nave 
Kidneys Transplanted
On Conservave Rx or 
Dialysis Transplanted
No 
Cirrhosis
Compensated 
Cirrhosis [2]
Decompensated 
Cirrhosis [3]
No 
Cirrhosis
Compensated 
Cirrhosis [2]
Decompensated 
Cirrhosis [3]
Selected Protocol E2:
Paritaprevir 
(150 
mg)/ritonav
ir (100 mg) 
and 
ombitasvir 
(25mg)  
(Querevo)*
+ Ribavirin
B2: Ledipasvir 
90mg+ 
Sofosbuvir 
400mg  
(Harvoni)+ 
Ribavirin
E2: Paritaprevir (150 
mg)/ritonavir (100 mg) 
and ombitasvir (25mg)  
(Querevo*)+ Ribavirin
D3: Daclatasvir  
60mg (Daklinza)
+ Sofodbuvir 
(Sovaldi) 400mg 
+ Ribavirin 
D3: Daclatasvir  (Daklinza) 60mg + Sofodbuvir
(Sovaldi) 400mg + Ribavirin
Basis of 
recommendaon
PEARL-I 
(GT-4); 
AASLD-I-LB
SOLAR-2 (GT-
4); AASLD-I-
LB; EASL A1
RUBY-I (GT-1); AASLD-Iib-
LB; EASL A1
 ALLY-1 (GT-I) ; 
AASLD-I-LB; EASL 
A1
ALLY-1 (GT-I) ; AASLD-I-LB; EASL A1
Alternave 
Protocol 1
B2: 
Ledipasvir
90mg+ 
Sofosbuvir 
400mg  
(Harvoni)+ 
Ribavirin
D3:
Daclatasvir 
(Daklinza)
60mg+ 
Sofodbuvir 
(Sovaldi)
400mg + 
Ribavirin 
C1*: Simeprevir (Olysio)
150mg+  Sofosbuvir 
(Sovaldi) 200mg without 
Ribavirin
E2: Paritaprevir (150 
mg)/ritonavir (100 mg) and 
ombitasvir (25mg)  (Querevo)* + 
Ribavirin
Basis of 
recommendaon
SYNERGY 
(GT-4); ION-
1 (GT-1); 
AASLD IIb-
LB 
ALLY-1 (GT-1); 
AASLD-I-
LB;EASL A1 Ram et al (Ref 32) CORAL-1 (GT-1); AASLD-I-LB
Alternave 
Protocol 2
C2: Simeprevir (Olysio)
150mg+  Sofosbuvir (Sovaldi) 
400mg + Ribavirin in the 
presence of cirrhosis
Basis of 
recommendaon
COSMOS 
(GT1); 
EASL B2
EASL B2
Ribavirin dose [4]
Protocols B,C,E 2: Body 
weight-based 1000 mg [<75 
kg] or 1200 mg [>75 kg]  
daily; Protocol D3: Daily 
ﬁxed dose 600mg
200 mg daily to be reduced if not tolerated to 
200mg 3 mes weekly. If on dialysis, 200mg 4 
hours before dialysis 3 mes weekly
200 mg daily to be reduced if not tolerated to 
200mg 3 mes weekly. If on dialysis, 200mg 4 
hours before dialysis 3 mes weekly
Treatment duraon 
with RBV
12 weeks 12 weeks 12 weeks
Treatment duraon 
without RBV
12 weeks 
OR 24 
weeks in 
the 
presence 
of cirrhosis
24 weeks 12 
weeks
24 weeks 12 weeks 24 weeks
Remarks
(*) For GT-4 
only. Add 
Dasabuvir 
250mg 
b.i.d. for 
GT-1
Modify doses 
of CyA, TAC, 
SIR, EVE 
according to 
desired blood 
levels
(*) For GT-4 only. Add 
Dasabuvir 250mg b.i.d. 
for GT-1 
Reduce doses of CyA, TAC, SIR, EVE according
to desired blood levels
Use cauon
with Protocol 
E [5]
Avoid
Protocol E
Use cauon
with Protocol E [5]
Avoid
Protocol E
1 Estimated by MDRD(4) equation.
2 >F3 by Fibroscan or equivalent chemical model.
3 Child Pugh score Class B-7 or higher.
4 Withdraw if not tolerated or hemoglobin level drops by 2 g/dl despite Erythropoietin treatment.
5 Use only by a transplant expert.
Antiviral treatment prioritization in HCV-infected patients 397
398 H. El-Fishawy et al.E2: Fixed-dose combination of paritaprevir (150 mg)/ritonavir
(100 mg) and ombitasvir (25 mg) (Viekerax, Technivie,
Qurevo) and weight-based ribavirin (1000 mg [<75 kg]
to 1200 mg [>75 kg]) for 12 weeks (PEARL-1 Study
[38], FDA approved for GT-4 without cirrhosis or hepato-
cellular failure).
E2*: Fixed-dose combination of paritaprevir (NS3)/ritonavir
(CY450), ombitasvir (NS5A) and dasabuvir (NS5B-
Exviera) (AbbVie 3D, Viekera Pack) and weight-based
Ribavirin (1000 mg [<75 kg] to 1200 mg [>75 kg]) for
12 weeks (CORAL-I trial post-transplant [39]).
E3*: Fixed-dose combination of paritaprevir (NS3)/ritonavir
(CY450), ombitasvir (NS5A) and dasabuvir (NS5B-
Exviera) (AbbVie 3D, Viekera Pack) and ribavirin in
adjusted doses for renal insufﬁciency (RUBY-I trial in
GT-1 [40]).
Adverse reactions. This protocol is well tolerated. One-third of
patients complain of fatigue, up to asthenia in half of them.
Less common side effects include skin reactions, myalgias,
nausea and insomnia. Hyperbilirubinemia with >5 fold-
elevation of hepatic transaminases occurs in 1% of cases, yet
up to 25% in women receiving estrogen therapy. While this
is usually transient, progression to severe hepatic failure has
been reported in patients with advanced cirrhosis, which war-
ranted a relevant FDA warning.
Ribavirin adverse reactions. Since many protocols include
Ribavirin, its signiﬁcant side effects may be superadded to
those of the individual protocols. Ribavirin administration,
by its own right, is associated with fatigue in about two-
thirds of cases, headache in one half and insomnia, irritability,
fever, nausea and dermatitis in one-third. Less common side
effects include arthralgias and myalgias, dizziness, diarrhea
and shortness of breath. Owing to its retention in patients with
impaired kidney function, many of these side effects are aug-
mented, in addition to the development of Coombs negative
hemolytic anemia that can be very severe in CKD Stages
IV–V.
Re-treatment protocols
XIII. We recommend re-treatment of patients that do not
achieve a SVR or recur after treatment. The choice of re-
treatment protocol depends on the failed initial protocol as
follows:
 Those with failed Interferon + Ribavirin protocol should
be treated according to the same recommendations for
treatment-naı¨ve patients (AASDL-IIa, L-B; EASL-A1).
 Patients with failed second-wave DAAs and that have no
urgent indication for retreatment, may wait until more reli-
able data are obtained by randomized clinical trials (EASL-
A1).
 Those who are indicated for treatment may use a different
protocol that includes ribavirin, for 12 weeks. This may
be extended to 24 weeks if the liver pathology is more
advanced (F4) or the platelet count persists below 75,000/
cmm, which is a predictor of poor response (EASL-B1).
The following successful re-treatment protocols have been
reported in small clinical trials: Protocol C2 for failure with any of Protocols B or D.
 Protocol B2 or D2 for failure with any Protocol C.
 Protocol B2, C2 or D2 for failure with any Protocol E.
Viral co-infection
XIV. Patients with viral co-infection should be granted high
priority for treatment, regardless of the stage of liver disease,
owing to the rapidly progressive organ damage and potential
of infectivity to the community [AASLD-IDSA-I, LB].
HBV co-infection
Patients should be treated with the same protocols as HCV
mono-infected patients (Protocol-B1) [AASLD-IDSA-IIa-
LC]. If HBV replicates at a signiﬁcant rate, concurrent HBV
nucleoside/nucleotide analogue therapy is indicated [41]
(Protocol-B1) (EASL-2015).
HIV co-infection
Patients co-infected with HCV and HIV have higher HCV-
RNA levels, higher rate of HCV persistence and faster progres-
sion to cirrhosis and end stage liver disease. The same IFN-free
HCV treatment recommendations for HIV/HCV co-infected
persons as for those with HCV-only infection, as the virologi-
cal results of therapy are identical [42]. However diligence is
due for potential drug–drug interactions with HIV medications
(EASL-A1) and (I-B, AASLD-IDSA-2015).
Drug–drug interactions
XV. We suggest using an automated drug compatibility checker
for identifying potential drug–drug interactions in between the
selected DAA protocol and contemporary medications for co-
morbid conditions [Opinion].
Historically, the interaction in between sofosbuvir and
amiodarone was the earliest life threatening complication, hall-
marked by bradycardia and cardiac arrest. Interaction was
subsequently reported in between DAAs and amlodipine, beta
blockers, psychoactive drugs, proton pump inhibitors,
substrates or for Cytochrome P450 and P-glycoprotein and
many others [43]. Adverse reactions to other drugs are
updated, by law, in different online databases as well as
drug inserts. As mentioned earlier, we recommend checking
for such interactions through an automated resource, in order
to keep pace with the rapid expansion of information in this
area.
Discussion
Extrahepatic manifestations of HCV infection constitute a
broad spectrum of multisystem involvement due to a combina-
tion of cytotoxic and immunologically-mediated injury. The
latter may be propagated by autoimmune mechanisms, which
may not be cured by merely eradicating the infection. We have
limited our prioritization to conditions that have proved by
evidence to respond to HCV treatment. This does not deny
potential beneﬁt in many other extrahepatic manifestations,
whether the infection is causal or associated, yet they need evi-
dence to claim priority.
Antiviral treatment prioritization in HCV-infected patients 399Owing to the complexity of extrahepatic manifestations,
and the frequency of associated renal damage, we opted to
provide multiple choices for different clinical settings (Table 5),
which provides room for enlightened individualization of
treatment on case-to-case basis.
Liver disease
Many clinical trials have shaped the preferred protocols
according to three levels of structural and functional liver
damage, namely chronic liver disease without cirrhosis, that
with cirrhosis, and decompensated cirrhosis. All protocols
included in our recommendations achieve a SVR12 over
90% following 12-week treatment in patients without cirrhosis.
While most protocols include ribavirin, they can still be used
without it for a price of slightly reduced SVR12 and higher
possibility of recurrence.
The presence of cirrhosis calls for obligatory inclusion of
ribavirin to improve efﬁcacy of the 12-week protocols and
reduce the chance of NS protein mutation. Treatment may
be extended to 24 weeks if the parameters of response are
unsatisfactory. Fortunately some ribavirin-free protocols are
still effective when used for 24 weeks in ribavirin-intolerant
patients (Table 5).
Decompensated cirrhosis constitutes a signiﬁcant challenge,
since most patients are ribavirin-intolerant, and many would
further decompensate with the initiation of treatment. Of our
selected protocols, daclatasvir offers a signiﬁcant step forward
when combined with sofosbuvir even without ribavirin (Proto-
col D – Table 5). By way of contrast, Protocol E is contraindi-
cated owing to the risk of hepatic failure or death, according to
a recent FDA warning.
Kidney disease
Since most DAAs are metabolized by the Cytochrome P450 in
the liver and intestinal wall, the kidney has a minimal role in
their excretion, ranging from 1% to 13%. So, even moderate
degrees of renal insufﬁciency do not require modiﬁcation of
protocol priorities or drug doses. This is in sharp contrast to
older treatment protocols including interferon and ribavirin.
Both are mainly metabolized in the kidneys, which are respon-
sible for elimination of 90% [44] and 61% [45] respectively of
administered single doses, hence the need for caution if the
eGFR is less than 50% of normal.
Severe impairment of kidney function, deﬁned as
eGFR< 30 ml/min/1.73 sqm (CKD stages IV and V) consti-
tutes a barrier to using Interferon or ribavirin, as well as a sig-
niﬁcant constraint to using several DAAs, which tend to build
up signiﬁcantly high blood levels along the course of treat-
ment. Sofosbuvir-containing regimens were reported in the
HCV-TARGET study [8] to impair kidney function in 5 of
17 (29%) patients with eGFR< 30 ml/min/1.73 sqm and 6
of 56 (11%) of those with eGFR 30–45 ml/min/1.73 sqm.
The manufacturer of Harvoni (Protocol B) explicitly does
not recommend using it with severe renal impairment due to
lack of data [46]. Despite favorable pharmacokinetics, there
are no RCTs on daclatasvir in this subset of patients. On the
other hand, the sofosbuvir-free protocol E, with or without a
small dose of ribavirin, has been FDA approved for patients
with severe renal impairment, on the basis of the RUBY-1trial. Although the latter included only patients with GT-1
infection, it proves the concept of safety with very low eGFR.
The earlier proof of efﬁcacy in GT-4, provided in the PEARL-
1 trial makes Protocol E most appropriate for Egyptian
patients with eGFR < 30 ml/min/1.73 sqm. It is important
to note the genotype constraint on using this protocol, where
dasabuvir is included only for GT-1. This imposes the necessity
of genotyping prior to embarking on a Viekera family
protocol.
While the drug pharmacokinetics in severe renal impair-
ment apply to those on regular dialysis, the latter adds con-
founding factors including drug dialyzability and unstable
internal environment. Dialyzability is the complex outcome
of the drug’s molecular size, conﬁguration and charge, and
the extent of its protein binding. Differences in these factors
in between DAAs make it difﬁcult to predict the pharmacoki-
netic skewing imposed by dialysis, which reﬂects on efﬁcacy as
well as safety. Unfortunately very few pharmacokinetic studies
and even fewer clinical observations have been made in the
dialysis population. Yet, on the basis of available data, the
most appropriate for hemodialysis patients seems to be Proto-
col E, achieving 100% SVR12 in the RUBY-1 trial. Slightly
inferior results (10/13) have been reported in a small number
of patients receiving full dose simeprevir with either daily half
dose or alternate day full dose sofosbuvir (Protocol C1*) [32].
Kidney transplant recipients
The pharmacokinetics of antiviral agents in kidney transplant
recipients are inﬂuenced by two factors: graft function and
drug–drug interactions.
The impact of graft function is the same as that of native
kidneys. So, recipients in stages I–III CKD can be treated
according to the general recommendations, with due consider-
ation only to drug–drug interactions. In those with more
advanced graft dysfunction, the recommendations for severe
renal impairment apply.
Drug–drug interactions impose a lot of noise in choosing
protocols for transplant recipients. Since four of the main
immunosuppressive drugs used in transplantation, namely
cyclosporine, tacrolimus, sirolimus and everolimus are metab-
olized by Cytochrome P450 (CYP450), as most DAAs do, sub-
strate competition is expected to play a signiﬁcant role in the
metabolism of both. There is considerable variation in this
type of interaction. For example, the interaction in between
Cyclosporine and simeprevir is so clinically relevant that it is
recommended to avoid this combination all together (EASL-
B1). On the other hand, simeprevir may be used concomitantly
with Tacrolimus or Sirolimus, yet with frequent monitoring of
their blood levels. No dose adjustment is required for tacroli-
mus or cyclosporine with Sofosbuvir plus ribavirin, ledipasvir
or daclatasvir (EASL-A2).
The CYP450 interaction becomes even more relevant when
the enzyme is inhibited, leading to accumulation of both
immunosuppressive and antiviral drugs. The list of CYP450
inhibitors is immense, which constitutes the main challenge
in the selection of treatment protocol, as well as in monitoring
therapy. Of particular importance is ritonavir, included in E
protocols with the speciﬁc objective of protecting paritaprevir
by inhibiting CYP450. By essence of this effect, Protocol E
drugs are bound to augment the blood levels of the mentioned
400 H. El-Fishawy et al.immunosuppressive agents, which requires avoiding the use of
mTOR inhibitors all-together, dramatic dose reduction of
Tacrolimus to 0.5 mg weekly and Cyclosporine to one-ﬁfth
its dose before initiating HCV treatment (EASL-A2).
Clinical data obtained from liver transplants have shown
excellent results with B and D protocols, hence their
prioritization in this guideline. No dose adjustment is required
for tacrolimus or cyclosporine with either protocol (EASL-
A2).
While pre-transplant HCV eradication was highly desirable
in the interferon era, owing to the risk of graft loss if the dug
was administered after transplantation, this policy became
questionable with the availability of safe DAAs. This provides
considerable relief if transplantation becomes an urgent neces-
sity, including that from deceased donors. However, when it
can wait, we strongly recommend treating patients on the wait-
ing list to avoid the HCV-associated many-fold increased risk
of thrombotic microangiopathy and acute transplant glomeru-
lopathy in the early post-transplant period. Since pre-
transplant patients are essentially in severe renal failure, often
already on dialysis, respective recommendations in protocol
selection and drug doses apply.
Non-renal extrahepatic manifestations
There is no evidence that any of the currently available DAAs
is preferred speciﬁcally for the treatment of extrahepatic man-
ifestations of HCV infection. The choice of a treatment proto-
col should follow the same recommendations based on the
stages of liver and kidney disease. However, the integration
of antiviral treatment within the overall management strategy
in individual conditions warrants due consideration in the
management of cryoglobulinemia.
Cryoglobulinemia
Circulating cryoglobulins are frequently detected in patients
with chronic HCV infection, but the clinical syndrome of
Cryoglobulinemic Vasculitis as deﬁned in the AASLD Classi-
ﬁcation [20] occurs only in 1–2.5% [47] of patients. It is this
subgroup that requires treatment before receiving DAAs.
Patients with asymptomatic cryoglobulinemia, and those with
mild manifestations as arthralgia, fatigue or purpuric skin
eruptions (Meltzer triad) may be treated according to the gen-
eral recommendations as described above.
Patients with minor intermittent inﬂammatory signs, such
as arthritis, without major organ involvement rapidly respond
to low-dose steroids, without undue delay in starting antiviral
treatment. It is noteworthy that HCV-associated peripheral
arthritis can also occur without cryoglobulinemia. While
response of this form to interferon-based treatment is conﬂict-
ing [48], the effect of virological cure by DAAs has not been
speciﬁcally addressed in any randomized trials.
On the other hand, in those with signiﬁcant organ involve-
ment as the heart, brain or kidneys, induction treatment is
indicated with intravenous pulses of methyl prednisolone
(10–15 mg/kg/dose for 3–5 consecutive days) followed by IV
Cyclophosphamide (10 mg/kg). Maintenance immunosuppres-
sion is required following successful induction [49].
Alternatively, Rituximab may be used to eliminate the
active B-lymphocyte clone producing the cryoglobulins. We
recommend a weekly dose of 375 mg/m2 for four doses. Thesame monoclonal antibody may be used for maintenance of
remission in a ﬁxed dose of 200–500 mg every 6–9 months [50].
Therapeutic plasma exchange (TPE) may be needed to
induce remission in patients with more fulminant or catas-
trophic cryoglobulinemic vasculitis [51]. Double-ﬁltration
plasmapheresis is preferable, where available, for the selective
removal of pathogenic immunoglobulins while preserving
other, essential components [52]. Maintenance immunosup-
pression remains essential following this induction course.
Antiviral treatment may be initiated upon induction of ini-
tial remission of the manifestations of cryoglobulinemic vas-
culitis. Interferon is not preferable since it may exacerbate
disease activity, and the virological response rate is modest
[53]. DAAs may be used according to the general recommen-
dations based on liver and kidney staging. Unfortunately,
there are no published data on the outcome of such treatment
in cryoglobulinemia. An Egyptian study is underway to answer
this question in GT-4, including SVR-12 in the face of
immunosuppressive therapy and the potential of recurrence
of cryoglobulinemia (Egyptian STDF, protocol 15083).
Malignant lymphomas
There is convincing evidence that chronic HCV infection is
causally related to B-Cell Non-Hodgkin lymphoma. Several
reports have shown regression of the lymphoma upon success-
ful viral elimination, which justiﬁes our recommendation to
prioritize treatment of this condition despite the lack of RCTs.
We also suggest treatment of other lymphomas on the basis
statistical evidence of their reduced incidence after interferon
treatment [15] or case reports of clinical regression [14].
Other extrahepatic manifestations
Despite the evidence of a causal role of HCV in the pathogen-
esis of other extrahepatic manifestations (as outlined in Secti
on ‘Indications for treatment’ above), there is no hard evidence
of their regression following HCV elimination. Accordingly,
the strength of treatment recommendation in these conditions
remains meager, stopping short at the level of ‘‘suggestion”
whether in this set of guidelines, or in other international
guidelines as the EASL or AASLD.
Conclusions
Recognizing the clinical and epidemiological impact of extra-
hepatic manifestations of HCV infection, independently from
the extent of liver injury, we identiﬁed 7 compelling and 10
indications for antiviral treatment. The former include HCV-
associated and certain other glomerulopathies, dialysis and
pre- and post-renal transplantation, cryoglobulinemic vasculi-
tis and Non-Hodgkin’s lymphoma. We reviewed different
treatment protocols based on the available DAAs in Egypt,
encoded and prioritized their use according to speciﬁc criteria
to optimize their beneﬁt. We concluded that any of the men-
tioned protocols can be effectively and safely used for 12-
week treatment in all patients with extrahepatic manifestations
without cirrhosis and with eGFR above 30 ml/min/1.73 sqm.
Ledipasvir–Sofosbuvir or Simeprevir–sofosbuvir protocols
are readily available in the country and lead to impressively
high SVR12. Patients with compensated cirrhosis usually
respond to a ribavirin-containing protocol, and yet they may
need to extend the duration of treatment to 24 weeks.
Antiviral treatment prioritization in HCV-infected patients 401Daclatasvir-based protocols are recommended for those with
decompensated cirrhosis, while the paritaprevir/ritonavir
+ ombitasvir ± Dasabuvir protocol (Viekera family) is con-
traindicated. The choices are much more limited in patients
with eGFR< 30 ml/min/1.73 sqm, including those on dialy-
sis, where the Viekera family protocols are currently the most
suitable. In transplanted patents, caution is due to avoidance
of the pharmacokinetic interaction with the Cytochrome-
P450 enzyme system, in-between immunosuppressive agents
and most DAAs, particularly the Viekera family. Factors that
modify the choice of DAAs include previous treatment failure,
co-infection with other viruses, and the concomitant adminis-
tration of other medications for comorbid conditions. Patients
with signiﬁcant immune-mediated injury as cryoglobulinemic
vasculitis may need concomitant treatment with immunosup-
pressive agents.Funding
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